Merck also goes for all-comers in adjuvant lung
The Kandlelit-013 trial of calderasib plus Keytruda in adjuvant NSCLC will start in April.
Kairos expands lung resistance strategy
The company will license EGFR and cMet inhibitors from Celyn.
BioNTech's patritumab me-too advances
The company's partner MediLink will start a pivotal trial of beruzatatug pelitecan in lung cancer.
The relentless march of VEGF bispecifics
Two new pivotal Chinese first-line trials have started in lung cancer.
Astellas makes its KRAS degrader choice
The company discontinues one of its two KRAS G12D degraders.
Datroway and Trodelvy's new breast cancer battle
But the Astra/Daiichi ADC stumbles in lung cancer.
Pumitamig pivotal trials come in pairs
Bristol will test the bispecific in two new lung indications.
